Related Experiment Video
Updated: Aug 12, 2026

Development of an Insert Co-culture System of Two Cellular Types in the Absence of Cell-Cell Contact
Published on: July 17, 2016
Angiogenesis in chronic myeloproliferative diseases
F Di Raimondo1, G A Palumbo, S Molica
1Institute of Hematology, University of Catania, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy. diraimon@sirio-oncology.it
Abstract:
Increased angiogenic activity has been demonstrated in myelofibrosis with myeloid metaplasia (MMM), chronic myeloid leukemia (CML), and essential thrombocythemia (ET) by both bone marrow microvessel density evaluation and measurement of circulating angiogenic factors. MMM is probably the disease with the more pronounced angiogenesis among myeloproliferative disorders but the significance of this finding remains speculative since the angiogenic activity is not correlated with any of the clinical and laboratory features of the disease. Circulating serum levels of angiogenic factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) were found increased in MMM, CML and ET but the frequent thrombocytosis that accompanies these diseases could limit the interpretation of these data since platelets and megakaryocytes may be considered a major source at least for VEGF. However, CML patients treated with interferon were found to have lower VEGF and HGF levels than untreated or hydroxyurea-treated patients, thus suggesting a possible antiangiogenic mechanism of this drug. In addition, preliminary experiences with the antiangiogenic drug thalidomide have shown therapeutic activity in some myeloproliferative disorders.
Related Concept Videos
Abnormal Proliferation
Mechanism of Angiogenesis
Regulation of Angiogenesis and Blood Supply
Differentiation of Common Myeloid Progenitor Cells
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Chronic Inflammation: Introduction

